News Sentiment

PULM sentiment intelligence

Pulmatrix Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 49 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.72 Week of 10 Jul 2026
Weighted tone 49/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Deals and strategy

72/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+0.0% over one week, +22.9% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Pulmatrix (NASDAQ: PULM) to Merge with Eos; 75.2M Shares to Be Issued

Market Reaction

Balanced read

46/100 confidence

News tone and price action are not far from neutral.

Primary event Deals and strategy 72/100 classification
One-week reaction 0.0% Price digesting
Trend fit Trend inactive 22.9% over four weeks
Fair value -51.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 37
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Stock Titan 7
TradingKey 7
PR Newswire 6
Market source 5
Moomoo 2
Finviz 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Earnings 16
Deals and strategy 16
Market update 15
Analyst action 1
Capital return 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
Moomoo Direct company coverage

Pulmatrix | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions - moomoo

This article states that Pulmatrix has filed under Securities Act Rule 425. This filing is in connection with various prospectuses and communications related to business combination transactions. The document itself is not provided in this snippet.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 09:40
Source
Moomoo
Finviz Direct company coverage

PULM - Pulmatrix Inc Latest SEC Filings

This article provides the latest SEC filings and detailed financial data for Pulmatrix Inc. (PULM). It includes key financial metrics, stock performance, insider ownership, institutional ownership, and analyst recommendations, offering a comprehensive overview of the company's cu

Tone
Neutral 50/100
Event
Analyst action
Published
06 Jul 2026 19:39
Source
Finviz
TradingView Direct company coverage

Enterprise value to EBITDA forward of Pulmatrix, Inc. – NASDAQ:PULM

This article displays the "Enterprise value to EBITDA forward" metric for Pulmatrix, Inc. (NASDAQ: PULM) on TradingView. It presents financial data for the company, noting the market status as closed with no trades. The page also provides general information about TradingView's o

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 00:41
Source
TradingView
TradingView Direct company coverage

Pulmatrix Inc Actuals & Estimates (NASDAQ:PULM)

This article provides an overview of Pulmatrix, Inc. (NASDAQ: PULM) stock, including its current price, market capitalization, historical performance, and financial data. It highlights the company's financial results, such as net income for the last quarter, and upcoming earnings

Tone
Negative 39/100
Event
Earnings
Published
26 Jun 2026 17:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Pulmatrix, Inc. – NASDAQ:PULM

This article provides the "Price to earnings forward" value for Pulmatrix, Inc. (NASDAQ: PULM). The value itself is not displayed, but the context indicates it's a financial metric for the pharmaceutical company. The page also lists various data providers for market and reference

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 10:11
Source
TradingView
TradingKey Direct company coverage

Pulmatrix Inc (PULM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Pulmatrix Inc (PULM), focusing on its price momentum, support and resistance levels, and insights from various technical indicators and moving averages. As of June 25, 2026, PULM shows a strong price momentum score and is trading with

Tone
Positive 61/100
Event
Market update
Published
25 Jun 2026 02:11
Source
TradingKey
TradingKey Direct company coverage

Pulmatrix Inc (PULM) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis of Pulmatrix Inc (PULM), stating its current valuation score is 7.17, ranking 255 out of 389 in the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -1.18, significantly below its recent high and above its re

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 00:39
Source
TradingKey
TradingKey Direct company coverage

Pulmatrix Inc (PULM) Financial Health: Profitability & Balance Sheet Analysis

Pulmatrix Inc (PULM) currently has a financial score of 6.80, placing it 210th out of 388 companies in the Biotechnology & Medical Research industry. The analysis indicates robust financial status but low operating efficiency. Several key financial data points such as total asset

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 09:10
Source
TradingKey
TradingKey Direct company coverage

Pulmatrix Inc (PULM) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a detailed risk assessment for Pulmatrix Inc (PULM), highlighting its volatility, financial risk, and investment risk. It notes the stock's beta of 1.95, indicating high sensitivity to market movements, and presents various metrics such as maximum drawdown,

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 08:18
Source
TradingKey
TradingKey Direct company coverage

Pulmatrix Inc (PULM) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article from TradingKey provides an earnings forecast for Pulmatrix Inc (PULM), noting that no earnings forecast score is currently available for the company. It highlights that the Biotechnology & Medical Research industry's average score is 8.13 and indicates that relevant

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 03:18
Source
TradingKey
TradingKey Direct company coverage

Pulmatrix Inc (PULM) Institutional Confidence

Pulmatrix Inc (PULM) currently has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 10.12%, an 8.89% increase quarter-over-quarter. James Simons is the largest i

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 23:40
Source
TradingKey
TradingKey Direct company coverage

Pulmatrix Inc (PULM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Pulmatrix Inc (PULM), covering business segments, regional revenue, and profit contribution. However, it states that the relevant data has not yet been disclosed by the company. The page displays Pulmatrix I

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 18:08
Source
TradingKey
Stock Titan Direct company coverage

Pulmatrix (NASDAQ: PULM) posts 2025 loss as Cullgen merger to give Cullgen 96.4%

Pulmatrix, Inc. has amended its 2025 annual report, revealing a net loss of $5.162 million and zero revenue, a significant decrease from 2024 due to the conclusion of its Cipla collaboration and reduced operating expenses. The company's future hinges on its pending merger with Cu

Tone
Negative 20/100
Event
Deals and strategy
Published
16 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Preclinical data: PTC-2105 boosts lean mass; Pulmatrix (NASDAQ: PULM) merger on track

Pulmatrix (NASDAQ: PULM) and Eos SENOLYTIX have released preclinical data for MitoXcel™ geropeptide PTC-2105, showing it significantly boosts lean mass, reduces fat, and improves physical function in animal studies, with prolonged benefits compared to GLP-1 comparators. The compa

Tone
Positive 66/100
Event
Deals and strategy
Published
05 Jun 2026 12:08
Source
Stock Titan
Stock Titan Direct company coverage

Pulmatrix (PULM) registers 490,910 shares for resale including 36,364 dividends

Pulmatrix, Inc. (PULM) has registered 490,910 shares of Common Stock for resale, including 36,364 Dividend Shares, stemming from the conversion of 1,000 Series B Convertible Preferred Shares. These shares, which convert at $2.20 and carry an 8% annual dividend payable in Common S

Tone
Neutral 50/100
Event
Capital return
Published
04 Jun 2026 10:39
Source
Stock Titan
Finviz Direct company coverage

PULM - Pulmatrix Inc Stock Price and Quote

This page provides a comprehensive overview of Pulmatrix Inc. (PULM) stock, including its latest stock price, financial metrics, and price performance. It also lists recent news and press releases from the company, detailing financial results, merger agreements, clinical trial up

Tone
Negative 40/100
Event
Deals and strategy
Published
01 Jun 2026 17:09
Source
Finviz
TradingView Direct company coverage

PULM: Merger with Eos SENOLYTIX announced; Q1 net loss narrows, cash at $3.3M

Pulmatrix (PULM) has announced a merger with Eos SENOLYTIX and successfully closed a $1 million private placement. In the first quarter of 2026, the company's net loss narrowed to $1.2 million due to reduced expenses, and it reported $3.3 million in cash reserves. Clinical develo

Tone
Positive 64/100
Event
Deals and strategy
Published
16 May 2026 09:10
Source
TradingView
Moomoo Direct company coverage

Press Release: Pulmatrix Announces First Quarter 2026 Financial Results

This press release from Pulmatrix announces its financial results for the first quarter of 2026. It will provide key financial figures, operational highlights, and potentially an outlook for the remainder of the year. Investors and stakeholders can expect to find details regardin

Tone
Neutral 50/100
Event
Earnings
Published
15 May 2026 19:09
Source
Moomoo
AlphaStreet Direct company coverage

Pulmatrix Releases Q1 2026 Financial Results

Pulmatrix, Inc. (PULM) reported a narrower loss for the first quarter of 2026, with a diluted loss per share of $0.32, showing an improvement from the prior year. The biopharmaceutical company is advancing its pipeline of inhaled therapeutic products for migraine prevention and r

Tone
Neutral 50/100
Event
Earnings
Published
15 May 2026 14:09
Source
AlphaStreet
PR Newswire Direct company coverage

Pulmatrix Announces First Quarter 2026 Financial Results

Pulmatrix, Inc. announced its first quarter 2026 financial results, highlighting a merger agreement with Eos SENOLYTIX and a private placement of preferred stock. The company is actively seeking to out-license or monetize its clinical assets, including iSPERSE™ technology and pro

Tone
Positive 62/100
Event
Deals and strategy
Published
15 May 2026 12:09
Source
PR Newswire
TradingView Direct company coverage

Pulmatrix, Inc. 1Q 2026: Net loss $(1.17M), EPS $(0.32) — 10-Q Summary

Pulmatrix, Inc. reported a first-quarter 2026 net loss of $(1.17M), or $(0.32) per share, showing an improvement from the prior year. The company is undergoing a strategic merger with Eos, has paused clinical development to explore monetization options for its pipeline programs (

Tone
Positive 60/100
Event
Deals and strategy
Published
15 May 2026 12:09
Source
TradingView
TradingView Direct company coverage

Pulmatrix reports Q1 2026 net loss $1.17M, cash $3.3M and announces merger agreement with Eos SENOLYTIX

Pulmatrix reported a Q1 2026 net loss of $1.17 million and held $3.3 million in cash by March 31, 2026. The company announced a merger agreement with Eos SENOLYTIX, expected to close in Q3 2026, and a $1.0 million private placement of preferred stock. Clinical development is curr

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 12:09
Source
TradingView
Stock Titan Direct company coverage

Pulmatrix (NASDAQ: PULM) Q1 loss, $1M raise and Eos merger plan

Pulmatrix (NASDAQ: PULM) reported a Q1 2026 net loss of $1.2 million, an improvement from $1.8 million a year prior, as operating expenses decreased. The company is actively pursuing a merger with Eos SENOLYTIX, expected to close in Q3 2026, and has raised $1.0 million through a

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 12:09
Source
Stock Titan
Stock Titan Direct company coverage

Pulmatrix (PULM) Q1 2026 shows tight cash, Eos merger and 94% pro forma dilution

Pulmatrix, Inc. (PULM) reported a Q1 2026 net loss of $1.2 million, an improvement from the previous year, primarily due to reduced operating expenses and paused R&D. The company concluded its first quarter with $3.3 million in cash and highlighted substantial doubt about its abi

Tone
Negative 18/100
Event
Deals and strategy
Published
15 May 2026 12:09
Source
Stock Titan